Pacira | PCRX - Pre Tax Profit


Pacira reported $5M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
Astellas Pharma JPY 186.51B 138.49B Jun/2026
Bristol-Myers Squibb USD 4.99B 1.75B Jun/2026
Cara Therapeutics USD -6.8M 1.9M Mar/2026
Coherus Biosciences USD -46.35M 90.86M Dec/2025
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Ironwood Pharmaceuticals USD 68.02M 30.2M Sep/2025
J&J USD 8.66B 839M Jun/2026
Ligand Pharmaceuticals USD -24.26M 81.04M Mar/2026
Nektar Therapeutics USD -43.09M 8.39M Mar/2026
Novo Nordisk DKK 33.8B 3.23B Jun/2025
Omeros USD -65.12M 21.27M Jun/2024
Pacira USD 5M 4.43M Mar/2026
Perrigo USD 105.4M 513.9M Jun/2026
Pfizer USD -653M 5.84B Jun/2026
Supernus Pharmaceuticals USD -57.65M 51.7M Jun/2026
Teva Pharmaceutical Industries USD -455M 1.21B Jun/2026
Xeris Pharmaceuticals USD 2.23M 8.85M Mar/2026
Zoetis USD 758M 3M Mar/2026